Estradiol is the main estrogen the ovaries make before menopause. Vaginal estradiol is a compounded prescription preparation that places a small, low dose of estradiol directly in the vagina, where the tissue changes of menopause cause symptoms. Bayview prepares it as a 0.01% or 0.02% cream in a VersaBase base, dispensed either in single-use 1 mL prefilled syringes or in a tube with an applicator, and as 0.1 mg vaginal suppositories.
Because the dose is low and delivered locally, most of the effect stays in the vaginal and lower urinary tissue and blood levels remain low. Only your provider can decide whether it is right for you, and a valid prescription is required.
How does it work?
After menopause, falling estrogen thins the lining of the vagina and lower urinary tract, reduces blood flow and natural lubrication, raises vaginal pH, and shifts the normal bacteria. Estradiol placed in the vagina restores estrogen signaling in that tissue: the lining thickens, moisture and elasticity improve, pH falls, and healthy lactobacilli return. Symptoms usually improve over a few weeks, with fuller benefit by about twelve weeks.
What is it used for?
Vaginal estrogen is used for genitourinary syndrome of menopause: vaginal dryness, burning and irritation, painful intercourse, and urinary urgency, frequency, and recurrent urinary tract infections related to menopause. The evidence for low-dose vaginal estrogen is strong. The 2025 AUA/SUFU/AUGS guideline on genitourinary syndrome of menopause gives a Strong Recommendation that clinicians offer local low-dose vaginal estrogen for vulvovaginal discomfort, dryness, and painful sex, states that it does not increase the risk of endometrial hyperplasia with atypia or endometrial cancer, and recommends against endometrial surveillance undertaken solely because a patient uses it. The Menopause Society's 2022 position statement likewise supports low-dose vaginal estrogen as first-line for isolated genitourinary symptoms. Bayview Pharmacy does not provide consultations or determine appropriateness.
What forms and strengths are available?
The strength and form are chosen by your provider. The cream is measured differently depending on how it is dispensed: a prefilled syringe delivers a fixed 1 mL, while a tube is measured with an applicator. The table below describes the options for education only.
| Form | Notes |
|---|---|
| 0.02% cream, 1 mL prefilled syringes | The most commonly dispensed form here; each syringe is a single measured dose |
| 0.01% cream, 1 mL prefilled syringes | A lower strength; note this matches the strength of the FDA-approved cream |
| Cream in a tube with applicator | For people who prefer a tube; dose measured on the applicator |
| Propylene glycol and paraben-free base | For sensitivity or reaction to ingredients in commercial creams |
| 0.1 mg vaginal suppository | A solid insert; some people find it less messy than a cream |
Forms are listed for education only and are not a statement that any option is better for a particular person. Your provider selects the strength, form, and schedule.
How is it used?
Use it exactly as your provider directs. A common approach is one dose inserted into the vagina at bedtime for about two weeks, then reducing to one to three times a week for maintenance. Bedtime dosing helps because lying down reduces leakage. With prefilled syringes, insert the syringe, press the plunger, and discard it; with a tube, fill the applicator to the mark your provider specified, insert, and wash the applicator afterward. Wash your hands before and after. Do not double up if you miss a dose. If symptoms have not improved after several weeks, tell your provider rather than increasing the dose yourself.
Side effects & safety
The most common effects are local: vaginal irritation or burning when starting, discharge, and sometimes mild breast tenderness or headache. These often settle as treatment continues. Cream and oil-containing bases can weaken latex condoms and diaphragms, so use another method of protection if that applies to you.
Labeling for menopausal hormone therapy is currently changing. In November 2025 HHS and FDA announced the removal of boxed-warning language about cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy products, and in February 2026 FDA approved those label changes for a first group of products including a topical vaginal estrogen, with further submissions pending. Compounded preparations carry no FDA-approved labeling of their own. Discuss your individual risks with your provider rather than relying on any general statement.
Who should not use it?
Based on the labeling for FDA-approved estradiol vaginal cream, estrogen is not appropriate for people with undiagnosed abnormal genital bleeding; known, suspected, or a history of breast cancer; other estrogen-dependent cancer; a current or past blood clot in the leg or lung; a history of stroke or heart attack; a known clotting disorder; liver disease; a known allergy to the product; or known or suspected pregnancy. The 2025 AUA/SUFU/AUGS guideline notes that use after breast cancer can be considered within multidisciplinary shared decision-making. Tell your provider your full health history, allergies, and all medications so they can determine whether it is appropriate for you.
How should it be stored?
Store as directed on your label, generally at controlled room temperature away from heat and light, and do not let it get above about 40 °C. Some suppository bases require refrigeration, so follow the label the pharmacy assigned. Keep it tightly closed and out of the reach of children, do not share it, and do not use it after the beyond-use date. Dispose of unused medication as your pharmacist directs.
Why is this compounded?
Several FDA-approved vaginal estrogen products are available, including estradiol vaginal cream, estradiol vaginal inserts, an estradiol vaginal ring, and conjugated estrogens vaginal cream. Compounding is appropriate when a patient needs something those products do not offer. The National Academies of Sciences, Engineering, and Medicine concluded in 2020 that compounded bioidentical hormone therapy should be restricted to two circumstances: an allergy to an ingredient in an FDA-approved product, or the need for a dosage form that is not commercially available. ACOG's 2023 clinical consensus similarly advises that compounded formulations should not be routinely prescribed when FDA-approved options exist, and that patients be counseled that compounded products lack FDA approval. As a 503A pharmacy, Bayview prepares each order to the prescriber's specification under USP <795> standards.
Clinical details for prescribers
Regulatory status. Estradiol is not a controlled substance. FDA-approved vaginal estrogens include estradiol vaginal cream 0.01% (Estrace and generics), estradiol vaginal inserts 10 mcg (Vagifem/Yuvafem), estradiol softgel inserts 4 and 10 mcg (Imvexxy), the estradiol vaginal ring (Estring), and conjugated estrogens vaginal cream (Premarin). The compounded 0.01% cream is the same strength as the approved cream and is therefore exposed to the “essentially a copy” restriction under FDCA 503A — please document the clinically significant difference for the individual patient (documented excipient sensitivity, or a dosage form the patient cannot otherwise use). The 0.02% cream and the 0.1 mg suppository are not marketed strengths or forms. Compounded preparations are not FDA-approved.
Dose equivalence caution. A 0.1 mg suppository contains roughly the estradiol in 1 g of 0.01% cream, but approximately 10 times a 10 mcg insert and 25 times a 4 mcg insert. Dose it as a cream equivalent, not as an insert equivalent.
Formulation & SIG. Estradiol 0.01% or 0.02% in VersaBase, dispensed as 1 mL prefilled syringes (8–36 mL) or in a 24–30 g tube; PG- and paraben-free base available; estradiol 0.1 mg vaginal suppositories (small shell), 24 count. Typical SIG: insert 1 mL intravaginally at bedtime for 14 days, then 1–3 times weekly. Prepared under USP <795>.
Evidence & clinical points:
- AUA/SUFU/AUGS 2025 GSM guideline: Strong Recommendation for local low-dose vaginal estrogen; no increase in endometrial hyperplasia with atypia or endometrial cancer; recommends against endometrial surveillance solely for its use.
- The Menopause Society 2022 position statement: first-line for isolated GSM; no routine progestogen required for endometrial protection at low local doses.
- NASEM 2020 and ACOG Clinical Consensus No. 6 (2023): restrict cBHT to ingredient allergy or an unavailable dosage form; salivary and serum hormone testing is not recommended for dosing.
- Menopausal hormone therapy labeling is in transition following the November 2025 HHS/FDA announcement and February 2026 label approvals; the endometrial cancer boxed warning was not removed for systemic estrogen-alone products.
- Monitoring: annual review; prompt workup of any postmenopausal bleeding. Routine estradiol level monitoring is not indicated for local therapy.
Ordering: e-prescribe to Bayview Pharmacy, Warwick RI, or fax 401-284-4506. Background: AUA/SUFU/AUGS GSM Guideline (2025); FDA summary of the NASEM cBHT study.
This is a prescription compounded medication and is not FDA-approved. This information is educational and is not medical advice. Your provider determines whether it is appropriate and sets the strength, form, and schedule.
